Head-to-head evidence
AstroStem vs Laromestrocel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Mesenchymal stem cell therapy · full Alzheimer's Disease pipeline
AstroStem
Developed by Nature Cell Co., Ltd. and partners
NCT03117738 · Phase 1/2 · completed
This trial was randomized and triple-blinded with a placebo control, which is a strong design foundation, but it enrolled only 21 participants (11 vs 10, with substantial dropout leaving just 7 per arm for the cognitive endpoint), making it severely underpowered. The primary cognitive endpoint (ADAS-Cog change) numerically favored placebo over AstroStem, and no p-value or confidence interval was reported for either primary outcome, so the primary comparison cannot be called a success for the drug.
Laromestrocel · Lomecel-B
Developed by Longeveron (NASDAQ: LGVN)
NCT05233774 · Phase 2 · completed
This trial was randomized, blinded, and placebo-controlled, but it enrolled only 50 patients and was designed primarily to test safety rather than a clinical outcome; cognitive measures were assessed only as secondary endpoints. The safety objective was met, but the small size and safety-focused design mean this trial does not by itself demonstrate a clinical benefit.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AstroStem's landscape · Laromestrocel's landscape